1.CMV colitis in a diabetic patient without administration of immunosuppressive agents.
Pil Soo SUNG ; Jin Sun JANG ; Bong Yun CHA
Korean Journal of Medicine 2010;79(5):504-505
No abstract available.
Colitis
;
Humans
;
Immunosuppressive Agents
2.Three Cases of Herpes Zoster Infections in immunosuppressants Patients.
Young Hoon SONG ; Bok Hee OH ; Woo Gill LEE
Journal of the Korean Pediatric Society 1982;25(11):1155-1158
No abstract available.
Herpes Zoster*
;
Humans
;
Immunosuppressive Agents*
3.Immunosuppressed model for experimental mice by cyclophosphamid
Journal of Vietnamese Medicine 2004;296(3):57-60
Study on white mices with age of 6-8 weeks, 18-20g body weight. They were divided into 3 groups: group 1 (control group): 30 mices; group 2: mices were immunesuppressed by 200mg cyclophosphamid per one kilogram of body weight, being checked after 5 days of injection; and 300mg cyclophosphamid per one kilogram (200mg on the first day and 100mg on the fifth day) and it was checked after 10 days of injection (group 3). The results: immunesuppressed model implemented by intraperitonial injection of 200mg per one kilogram of body weight checked after 5 days of injeciton. These parameters were used to assign the immune function
Immunosuppressive Agents
;
Mice
;
Animal Experimentation
;
Cyclophosphamide
4.A Case of Iatrogenic Kaposi's Sarcoma Developed in a Psoriasis Patient after a Long-term Use of Immunosuppressive Agents.
Jun Yeong PARK ; Ji Yun JUNG ; Bok Won PARK ; Eun Byul CHO ; Eun Joo PARK ; Kwang Ho KIM ; Kwang Joong KIM
Korean Journal of Dermatology 2017;55(6):372-374
No abstract available.
Cyclosporine
;
Humans
;
Immunosuppressive Agents*
;
Psoriasis*
;
Sarcoma, Kaposi*
5.A Case of Iatrogenic Kaposi's Sarcoma Developed in a Psoriasis Patient after a Long-term Use of Immunosuppressive Agents.
Jun Yeong PARK ; Ji Yun JUNG ; Bok Won PARK ; Eun Byul CHO ; Eun Joo PARK ; Kwang Ho KIM ; Kwang Joong KIM
Korean Journal of Dermatology 2017;55(6):372-374
No abstract available.
Cyclosporine
;
Humans
;
Immunosuppressive Agents*
;
Psoriasis*
;
Sarcoma, Kaposi*
6.The response to immunosuppressive agents in the adult patients with idiopathic nephrotic syndrome.
Seong Ho KIM ; Jae Hyung AHN ; Won Do PARK ; Tae Won LEE ; Chun Gyoo IHM ; Myung Jae KIM
Korean Journal of Nephrology 1992;11(4):377-385
No abstract available.
Adult*
;
Humans
;
Immunosuppressive Agents*
;
Nephrotic Syndrome*
7.Biosynthesis of immunosuppressant tacrolimus: a review.
Liqun JIN ; Di LU ; Minglin XING ; Xianwen WANG ; Zhiqiang LIU ; Yuguo ZHENG
Chinese Journal of Biotechnology 2023;39(8):3095-3110
Tacrolimus (FK506) is a 23-membered macrolide with immunosuppressant activity that is widely used clinically for treating the rejection after organ transplantation. The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation process, with the hope to address the technical bottlenecks for tacrolimus biosynthesis and improve tacrolimus production by fermentation engineering and metabolic engineering.
Tacrolimus
;
Immunosuppressive Agents
;
Fermentation
;
Macrolides
;
Anti-Bacterial Agents
8.Irreversible Hemorrhagic Complication of Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient with Systemic Lupus Erythematosus.
Ho Kyun KIM ; Hui Joong LEE ; Kyung Min SHIN
Journal of the Korean Society of Magnetic Resonance in Medicine 2013;17(2):144-148
Although most cases of posterior reversible encephalopathy syndrome (PRES) are reversible, irreversible lesions as a form of hemorrhage or infarction have been described. PRES as a complication of systemic lupus erythematosus (PRES-SLE) is associated with hypertension or use of immunosuppressive agents. We present a case of recurrent atypical PRES-SLE, which showed restricted diffusion in the first manifestation of SLE, resulted in parenchymal hemorrhagic transformations in the recurrent episode.
Diffusion
;
Hemorrhage
;
Humans
;
Hypertension
;
Immunosuppressive Agents
;
Infarction
;
Lupus Erythematosus, Systemic
9.A Case of Doxifluridine-Induced Multiple Atypical Moles on the Palm and Sole of a Patient Taking Immunosuppressive Agents.
Woon Kyong CHUNG ; Seong Min KANG ; Do Young RHEE ; Sung Eun CHANG ; Mi Woo LEE ; Jee Ho CHOI ; Kee Chan MOON
Korean Journal of Dermatology 2008;46(9):1257-1261
Doxifluridine is a pyrimidine derivative and is activated to 5-fluorouracil by pyrimidine phosphorylase. Multiple acral hyperpigmented macules have been reported in patients treated with systemic 5-fluorouracil or some of its prodrugs. However, there have been no reports of this adverse event being induced by doxifluridine. Herein we present a 42-year-old woman with multiple pigmented lesions on the palm and sole after chemotherapy with oral doxifluridine.
Adult
;
Female
;
Floxuridine
;
Fluorouracil
;
Humans
;
Hyperpigmentation
;
Immunosuppressive Agents
;
Prodrugs
;
Pyrimidines
10.Three Cases of Oral Lichen Planus Treated with Topical Tacrolimus.
Korean Journal of Dermatology 2006;44(4):521-523
Oral lichen planus (OLP) is a painful chronic inflammatory condition, that is often resistant to many therapeutic approaches, including immunosuppressive agents. Topical tacrolimus has recently been recognized as a safe and effective remedy in the treatment of OLP. We, rerein, describe 3 patients with oral lichen planus, who showed a substantial improvement after the use of topical tacrolimus ointment (0.1%). This topical agent was well tolerated in all 3 patients and could be used an effective medicine in controlling oral lesions of lichen planus.
Humans
;
Immunosuppressive Agents
;
Lichen Planus
;
Lichen Planus, Oral*
;
Tacrolimus*